艾素联合顺铂介入治疗30例晚期非小细胞肺癌的体会

Combination of docetaxel and cisplatin in the interventional treatment of advanced non-small cell lung cancer

目的观察艾素(国产多西紫杉醇)联合顺铂介入治疗晚期非小细胞肺癌的疗效及毒副反应。方法对经病理学或细胞学证实的30例晚期非小细胞肺癌患者给予艾素与顺铂联合介入治疗,其中艾素75mg/m2,患侧支气管动脉和周围静脉各1/2灌注;顺铂40mg,静脉滴注,第1～3天、21d为1周期,每例患者治疗两周期以上。结果全组完全缓解1例,部分缓解13例,稳定10例,进展6例,总有效率为46.7%。初治组有效率为60%,复治组有效率为33.3%。最常见的毒副反应为骨髓抑制,其余毒副反应均轻微可耐受。结论多西紫杉醇联合顺铂介入治疗晚期非小细胞肺癌有较好的疗效。

Objective To evaluate the efficacy and toxicity of the combination of docetaxel and cisplatin in the interventional treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods Thirty patients with locally advanced (stage Ⅲ) or metastatic (stage Ⅳ) NSCLC were enrolled into the study The patients received docetaxel 75 mg/m2 per day by bronchial artery and vein,and cisplatin 40mg2 on day 1 -3 of a 21-day cycle. Each patient should complete two cycles, Results An objective response rate was obtained in 46.7%of 30 patients (one complete and 13 partial response), whereas 10 patients had stable disease and 6 patients were progressive , The response rate was 60%(9/15) in the initial patients, and 33.3%(5/15) in the retreated patients. The main toxicities were leukopenia (26.7%in grade Ⅲ+Ⅳ) and thrombocytopenia (10%in grade Ⅲ+Ⅳ). Conclusion The combination of docetaxel and cisplatin by interventional treatment is a feasible, well-tolerated and active scheme in the treatment of advanced NSCLC.